Diabetes Mellitus in Patients With Autoimmune Hepatitis: Frequency, Risk Factors and Effect on Outcome

BackgroundTreatment for autoimmune hepatitis (AIH) includes corticosteroids, which are associated with the development of diabetes mellitus (DM). Reported new‐onset DM rates in patients with AIH have varied, and predisposing factors and prognostic implications are inadequately characterised.AimTo identify the frequency and predisposing factors for DM in AIH and its association with disease progression and mortality.MethodsRetrospective/prospective single‐centre study of 494 patients with AIH presenting 1987–2023, 466 receiving corticosteroids (454 prednisolone, 12 budesonide) and followed for (median (range) 9 (0–36) years).ResultsForty‐seven patients (10%) already had DM at AIH diagnosis. New‐onset DM subsequently developed in another 59 (13%). In those receiving prednisolone, new‐onset DM incidence was 8% ± 1% after 1 year and 14% ± 2% after 10 years (14‐ and 3‐fold higher than expected population rate), and was independently associated with older age, non‐Caucasian ethnicity, higher initial prednisolone dose, higher BMI at diagnosis and more weight gain after 2 years of follow‐up. New‐onset DM usually persisted despite stopping prednisolone.New‐onset DM and DM at any time were independently associated with all‐cause death/transplantation rate, along with previously established risk factors (older age, cirrhosis, lower ALT at diagnosis and failure of early ALT normalisation). New‐onset DM and DM at any time were also independently associated with cirrhosis development. Similar associations of new‐onset DM and DM at any time with liver‐related death/transplantation were significant on univariate but not multivariate analysis.ConclusionNew‐onset DM occurred in 13% of patients with AIH, was related to older age, non‐Caucasian ethnicity, higher prednisolone dose, higher BMI at diagnosis and weight gain; and was an independent predictor of all‐cause death/transplantation and of cirrhosis development, underlining the need to minimise steroid burden in AIH.